Bioreductive prodrugs as cancer therapeutics: Targeting tumor hypoxia

Chinese Journal of Cancer

Volumn 33, Issue 2, 2014, Pages 80-86

  Guise, Christopher P ^a   Mowday, Alexandra M ^a   Ashoorzadeh, Amir ^a   Yuan, Ran ^b   Lin, Wan Hua ^b   Wu, Dong Hai ^b   Smaill, Jeff B ^a   Patterson, Adam V ^a   Ding, Ke ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

Bioreductive; Clinical trial; Oxidoreductase; Prodrug; Tumor hypoxia

Indexed keywords

APAZIQUONE; BANOXANTRONE; BIOREDUCTIVE PRODRUG; CARBONATE DEHYDRATASE IX; CHLORMETHINE; CISPLATIN; CYTOCHROME P450 REDUCTASE; CYTOTOXIN; FLORTANIDAZOLE F 18; MITOMYCIN; N, N' BIS (2 BROMOETHYL) PHOSPHORODIAMIDIC ACID (1 METHYL 2 NITRO 1H IMIDAZOL 5 YL) METHYL ESTER; N,N' BIS(2 BROMOETHYL)PHOSPHORODIAMIDIC ACID (1 METHYL 2 NITRO 1H IMIDAZOL 5 YL)METHYL ESTER; OXIDOREDUCTASE; PORFIROMYCIN; PR 104; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SN 30000; SUPEROXIDE DISMUTASE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

CANCER GROWTH; DRUG MECHANISM; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOLECULARLY TARGETED THERAPY; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; REVIEW;

ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; AZIRIDINES; CELL HYPOXIA; HUMANS; INDOLEQUINONES; MOLECULAR STRUCTURE; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASMS; NITROGEN MUSTARD COMPOUNDS; NITROIMIDAZOLES; PHOSPHORAMIDE MUSTARDS; PRODRUGS; TRIAZINES;

EID: 84893499123     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10285     Document Type: Review

References (77)

1. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 1996,379:88-91.
2. Kim CY, Tsai MH, Osmanian C, et al. Selection of human cervical epithelial cells that possess reduced apoptotic potential to lowoxygen conditions. Cancer Res, 1997,57:4200-4204.
3. Chan N, Koritzinsky M, Zhao H, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res, 2008,68:605-614.
4. Semenza GL. Regulation of cancer cell metabolism by hypoxiainducible factor 1. Semin Cancer Biol, 2009,19:12-16.
5. Vaupel P. Metabolic microenvironment of tumor cells: a key factor in malignant progression. Exp Oncol, 2010,32:125-127.
6. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer, 2002,2:38-47.
7. Vaupel P, Hoeckel M. Predictive power of the tumor oxygenation status. Adv Exp Med Biol, 1999,471:533-539.
8. Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis, 2009,26:19-34.
9. Kim Y, Lin Q, Glazer PM, et al. Hypoxic tumor microenvironment and cancer cell differentiation. Curr Mol Med, 2009,9:425-434.
10. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene, 2010,29:625-634.
11. Denny WA. The role of hypoxia-activated prodrugs in cancer therapy. Lancet Oncol, 2000,1:25-29.
12. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol, 1996,41:31-39.
13. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev, 2007,26:225-239.
14. Huxham LA, Kyle AH, Baker JHE, et al. Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res, 2004,63:6537-6541.
15. Minchinton AI, Tannock IF. Drug penetration in solid tumors. Nat Rev Cancer, 2006,6:583-592.
16. Tredan O, Galmarini CM, Patel K, et al. Drug resistance and the solid tumour microenvironment. J Natl Cancer Inst, 2007,99:1441-1454.
17. Denny WA. Hypoxia-activated anticancer drugs. Expert Opinion Ther Pat, 2005,15:635-646.
18. Chen Y, Hu L. Design of anticancer prodrugs for reductive activation. Med Res Rev, 2009,29:29-64.
19. Stratford IJ, Workman P. Bioreductive drugs into the next millennium. Anticancer Drug Des, 1998,13:519-528.
20. Guise CP, Abbattista MR, Tipparaju SR, et al. Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia. Mol Pharmacol, 2012,81:31-40.
21. Patterson AV, Ferry DM, Edmunds SJ, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA crosslinking agent PR-104. Clin Cancer Res, 2007,13:3922-3932.
22. Singleton RS, Guise CP, Ferry DM, et al. DNA crosslinks in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism and cytotoxicity. Cancer Res, 2009,69:3884-3891.
23. Guise CP, Wang, A, Thiel, A, et al. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol, 2007,74: 810-820.
24. Guise CP, Abbattista M, Singleton RS, et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res, 2010,70:1573-1584.
25. Duan JX, Jiao H, Kaizerman J, et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem, 2008,51:2412-2420.
26. Meng F, Evans JW, Bhupathi D, et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther, 2012,11:740-751.
27. Sun JD, Liu Q, Wang J, et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res, 2012,18:758-770.
28. Liu Q, Sun JD, Wang J, et al. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol, 2012,69:1487-1498.
29. Weiss GJ, Infante JR, Chiorean EG, et al. Phase 1 study of the safety, tolerability and pharmacokinetics of TH-302, a hypoxiaactivated prodrug, in patients with advanced solid malignancies. Clin Cancer Res, 2011,17:2997-3004.
30. Zeman EM, Brown JM, Lemmon MJ, et al. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys, 1986,12:1239-1242.
31. Shinde SS, Maroz A, Hay MP, et al. Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine). J Am Chem Soc, 2010,132:2591-2599.
32. Wang J, Biedermann KA, Brown JM. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res, 1992,52:4473-4477.
33. Daniels JS, Gates KS, Tronche C, et al. Direct evidence for bimodal DNA damage induced by tirapazamine. Chem Res Toxicol, 1998,11:1254-1257.
34. Patterson AV, Saunders MP, Chinje EC, et al. Enzymology of tirapazamine metabolism: a review. Anticancer Drug Des, 1998,13:541-573.
35. Patterson AV, Saunders MP, Chinje EC, et al. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer, 1997,76:1338-1347.
36. Patterson AV, Barham HM, Chinje EC, et al. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer, 1995,72:1144-1150.
37. Baker MA, Zeman EM, Hirst VK, et al. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res, 1988,48:5947-5952.
38. Siim BG, Menke DR, Dorie MJ, et al. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res, 1997,57:2922-2928.
39. Brown JM, Lemmon MJ. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys, 1991,20:457-461.
40. Marcu L, Olver I. Tirapazamine: from bench to clinical trials. Curr Clin Pharmacol, 2006,1:71-79.
41. Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol, 2005,23:79-87.
42. Miller VA, Ng KK, Grant SC, et al. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol, 1997,8:1269-1271.
43. Treat J, Johnson E, Langer C, et al. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol, 1998,16:3524-3527.
44. Rischin D, Peters LJ, O'Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol, 2010,28:2989-2995.
45. Williamson SK, Crowley JJ, Lara PN Jr, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol, 2005,23:9097-9104.
46. Hicks KO, Siim BG, Jaiswal JK, et al. Pharmacokinetic/ pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res, 2010,16:4946-4957.
47. Patterson LH, Craven MR, Fisher GR, et al. Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. Oncol Res, 1994,6:533-538.
48. Patterson LH, McKeown SR, Robson T, et al. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des, 1999,14:473-486.
49. Raleigh SM, Wanogho E, Burke MD, et al. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int J Radiat Oncol Biol Phys, 1998,42:763-767.
50. Nishida CR, Lee M, Ortiz de Montellano PR. Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1. Mol Pharmacol, 2010,78:497-502.
51. Patterson LH, Murray GI. Tumour cytochrome p450 and drug activation. Curr Pharm Des, 2002,8:1335-1347.
52. Yakkundi A, McErlane V, Murray M, et al. Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Ther, 2006,13:598-605.
53. Chinje EC, Cowen RL, Kong Z, et al. Elevated inducible NOS activity in human fibrosarcoma HT1080 tumor cells enhances AQ4N reductive metabolism in vitro. Proc AACR, 2004,45:564.
54. McKeown SR, Hejmadi MV, McIntyre IA, et al. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer, 1995,72:76-81.
55. Patterson LH, McKeown SR, Ruparelia K, et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer, 2000,82:1984-1990.
56. Albertella MR, Loadman PM, Jones PH, et al. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res, 2008,14:1096-1104.
57. Kennedy KA, Rockwell S, Sartorelli AC. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res, 1980,40:2356-2360.
58. Haffty BG, Wilson LD, Son YH, et al. Concurrent chemoradiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys, 2005,61:119-128.
59. Ward TH, Coe N, Hargreaves R, et al. Toxicity, cellular uptake and DNA crosslinking studies on the novel bioreductive anticancer drug RH1. Br J Cancer, 2000,83:66.
60. Phillips RM, Hendriks HR, Peters GJ. EO9 (Apaziquone): from the clinic to the laboratory and back again. Br J Pharmacol, 2013,168:11-18.
61. Cowen RL, Patterson AV, Telfer BA, et al. Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of Mitomycin C in human breast cancer xenografts. Mol Cancer Ther, 2003,2:901-909.
62. Saunders MP, Jaffar M, Patterson AV, et al. The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. Biochem Pharmacol, 2000,59:993-996.
63. Plumb JA, Workman P. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer, 1994,56:134-139.
64. Plumb JA, Gerritsen M, Milroy R, et al. Relative importance of DTdiaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys, 1994,29:295-299.
65. Robertson N, Haigh A, Adams GE, et al. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DTdiaphorase activity and hypoxia. Eur J Cancer, 1994,30A:1013-1019.
66. Ross, D, Siegel, D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol, 2004,382:115-144.
67. Danson S, Ward TH, Butler J, et al. DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev, 2004,30:437-449.
68. Hendricksen K, Cornel EB, de Reijke TM, et al. Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer. J Urol, 2012,187:1195-1199.
69. Choudry GA, Stewart PA, Double JA, et al. A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br J Cancer, 2001,85:1137-1146.
70. Ware DC, Palmer BD, Wilson WR, et al. Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. J Med Chem, 1993,36:1839-1846.
71. Ahn GO, Botting KJ, Patterson AV, et al. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. Biochem Pharmacol, 2006,71:1683-1694.
72. Parker LL, Lacy SM, Farrugia LJ, et al. A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs. J Med Chem, 2004,47:5683-5689.
73. Denny WA, Wilson WR. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin Investig Drugs, 2000,9:2889-2901.
74. Hicks KO, Pruijn FB, Secomb TW, et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst, 2006,98:1118-1128.
75. Borad MJ, Reddy S, Uronis H, et al. Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer. Cancer Res, 2012,72 Suppl 1:abstract LB-121.
76. Chawla SP, Ganjoo KN, Adkins D, et al. A phase 2 study of TH-302 in combination with doxorubicin in advanced soft tissue sarcoma. Connective Tissue Oncology Society (CTOS) Annual Meeting, Chicago, USA 26-29 October, 2011.
77. Smaill JB, Jaiswal JK, Abbattista MR, et al. Mechanism of action of the hypoxia-activated irreversible pan-HER inhibitor SN29966. Mol Cancer Ther, 2011,10:A247.